I hope your May is off to a productive start, Cell & Gene readers.
Last month, the FDA released a statement by former FDA commissioner Scott Gottlieb, M.D., and Biologics Center director Peter Marks, M.D., Ph.D., on the FDA’s continued efforts to stop stem cell clinics and manufacturers from marketing unapproved products that put patients at risk. I caught up with Dr. Aaron Levine, associate professor, School of Public Policy at Georgia Institute of Technology, to get his take on the statement and how dubious stem cell clinics affect the good of the cell and gene sector.
Just recently, I interviewed Dr. Reni Benjamin, managing director, biotechnology equity research at Raymond James & Associates, about the panel he moderated at ARM’s 2019 Cell & Gene Therapy Investor Day. In the article, Dr. Benjamin explained how investors are thinking about the cell and gene therapy space in 2019.
During our interview, he and I also got to talking about indication crowding and whether it's a concern in cell and gene therapy. I found his insight helpful, and I believe you will, too.
Erin Harris, editor in chief
Follow me on Twitter